CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 66 enrolled
Drug / intervention
cyclosporinedrug
Likely dose
cyclosporine 6 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04979884
NCT04979884Phase 3Completed
CompareCT.gov

Safety and Therapeutic Efficacy of Cyclosporine Plus Standard of Care Treatment on ARDS in COVID -19 Patients at Alexandria University Hospitals in 2021: a Comparative Study

Alexandria University·interventional·Posted Jul 28, 2021·Updated May 14, 2025

In Brief

A Phase 3 clinical trial evaluating cyclosporine for COVID-19 Acute Respiratory Distress Syndrome and 2 related conditions. Completed, enrolled 66 participants across 1 site.

Detailed Summary

The study to evaluate the effect of cyclosporine ( IL2 inhibitor and antiviral) verse standard care treatment on decrease ADRS, hyper inflammation, hypercytokinemia, and the mortality rate

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Pulmonary Fibrosis
CountriesEgypt
CollaboratorsScience and Technology Development Fund (STDF), ,Egypt

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedJul 28, 2021
Enrollment StartJan 3, 2022
Primary CompletionSep 9, 2022
Study CompletionDec 9, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.9 years ago

Interventions

cyclosporinedrug

Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days